Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Eli Lilly (LLY) is expected to deliver Q2 revenue slightly above consensus on stronger-than-anticipa
Eli Lilly (LLY) is poised to outpace second-quarter sales consensus estimates as strong volume uptak
Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.
The Number $8.662 billion. That is what Mounjaro alone generated for Eli Lilly (NYSE:LLY) in the first quarter of 2026, a single product, a single quarter, up 125% year over year. The figure was disclosed in Lilly’s Q1 2026 earnings release on April 30, 2026, an actual reported figure. This key growth driver is what ... This $1,200 Stock Could Be the Next Massive Stock Split Opportunity
A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to keep risk management in mind.
Wall Street is getting more bullish on the pharma giant's shares.
While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.
Don't sleep on these medical device leaders.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.
Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial control of breast cancer drug Verzenios, a shift that raises fresh questions about how the stock’s premium valuation stacks up. See our latest analysis for Eli Lilly. Verzenios is only one piece of a much bigger story for Eli Lilly. The stock gave back some ground in the latest session as the share price fell 1.14% to US$1,200.06, yet it is still showing firm momentum with a 30 day share price...
The stock is down, but it isn't out yet.
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S
Construction at Pfizer’s former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues. The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the index, at more than 7%. Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.
Drug stocks got hit hard on Monday in what Jim Cramer called a “vicious rotation,” and the selloff looked like the usual crowded-trade unwind. Investors decided the Mounjaro story was played out. On Tuesday morning’s Mad Dash, Cramer walked through why he thinks that reading is wrong, and he had a fresh JPMorgan note flagging ... Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They’re Dead Wrong
Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.
Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.
Find insight on Eli Lilly, Vertex Pharmaceuticals, Raffles Medical and more in the latest Market Talks covering the health care sector.
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
July 7 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to capture a slice of a fast-growing sector dominated by Novo Nordisk and Eli Lilly.
Shares of Eli Lilly have risen by over 40% since the company last reported earnings.
Stock Market Today: The Dow Jones index rose, while tech futures sold off amid Samsung earnings. Micron and Sandisk plunged.
AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.
The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.